Abstract:Abstract The cytoprotective transcriptor factor nuclear factor erythroid 2– related factor 2 (NRF2) is part of a complex regulatory network that responds to environmental cues. To better understand its role in a cluster of inflammatory and pro-oxidative burden of lifestyle diseases that accumulate with age, lessons can be learned from evolution, the animal kingdom and progeroid syndromes. When levels of oxygen increased in the atmosphere, mammals required ways to protect themselves from the metabolic toxicity that arose from the production of reactive oxygen species. The evolutionary origin of the NRF2–Kelch-like ECH-associated protein 1 (KEAP1) signalling pathway from primitive origins has been a prerequisite for a successful life on earth, with checkpoints in antioxidant gene expression, inflammation, detoxification and protein homoeostasis. Examples from the animal kingdom suggest that superior antioxidant defense mechanisms with enhanced NRF2 expression have been developed during evolution to protect animals during extreme environmental conditions, such as deep sea diving, hibernation and habitual hypoxia. The NRF2–KEAP1 signalling pathway is repressed in progeroid (accelerated ageing) syndromes and a cluster of burden of lifestyle disorders that accumulate with age. Compelling links exist between tissue hypoxia, senescence and a repressed NRF2 system. Effects of interventions that activate NRF2, including nutrients, and more potent (semi)synthetic NRF2 agonists on clinical outcomes are of major interest. Given the broad-ranging actions of NRF2, we need to better understand the mechanisms of activation, biological function and regulation of NRF2 and its inhibitor, KEAP1, in different clinical conditions to ensure that modulation of this thiol-based system will not result in major adverse effects. Lessons from evolution, the animal kingdom and conditions of accelerated ageing clarify a major role of a controlled NRF2–KEAP1 system in healthy ageing and well-being.

Aging, NRF2, and TAU: A Perfect Match for Neurodegeneration?

Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: mechanisms and therapeutic implications

Nrf2: a dark horse in Alzheimer's disease treatment

Role of NRF2 in Pathogenesis of Alzheimer's Disease

Nrf2 activation in the treatment of neurodegenerative diseases: a focus on its role in mitochondrial bioenergetics and function

Transcription factor NRF2 as a promising therapeutic target for Alzheimer’s disease

Nrf2 Mediates the Expression of BAG3 and Autophagy Cargo Adaptor Proteins and Tau Clearance in an Age-Dependent Manner

A Perspective on Nrf2 Signaling Pathway for Neuroinflammation: A Potential Therapeutic Target in Alzheimer's and Parkinson's Diseases

An Overview of the Nrf2/ARE Pathway and Its Role in Neurodegenerative Diseases

Re-energising the brain: glucose metabolism, Tau protein and memory in ageing and dementia

The Interaction of mTOR and Nrf2 in Neurogenesis and Its Implication in Neurodegenerative Diseases

The Nrf2-HO-1 system and inflammaging

Tau proteins and senescent Cells: Targeting aging pathways in Alzheimer's disease

NRF2 Activation and Downstream Effects: Focus on Parkinson’s Disease and Brain Angiotensin

Understanding the role of the cytoprotective transcription factor nuclear factor erythroid 2-related factor 2—lessons from evolution, the animal kingdom and rare progeroid syndromes

Aging and neurodegeneration: From molecular mechanisms to therapeutic interventions

NRF2 in age-related musculoskeletal diseases: Role and treatment prospects

Nrf2 pathways in neuroprotection: Alleviating mitochondrial dysfunction and cognitive impairment in aging

Interplay among Oxidative Stress, Autophagy, and the Endocannabinoid System in Neurodegenerative Diseases: Role of the Nrf2- p62/SQSTM1 Pathway and Nutraceutical Activation

Interrelation of Oxidative Stress and Inflammation in Neurodegenerative Disease: Role of TNF

The putative contribution of cellular senescence to driving tauopathies